Pharmacokinetics Services Market Size, Growth, Share by 2031
The pharmacokinetics services market size is projected to reach US$ 874.96 million by 2031 from US$ 1,579.87 million in 2023. The market is expected to register a CAGR of 7.6% in 2023–2031. The increasing adoption of Big Data analytics is likely to remain a key pharmacokinetics services market trend.
Pharmacokinetics Services Market Analysis
Pharmacokinetic studies are being employed to determine several parameters such as human-equivalent doses (HED) level and no-observed effect level (NOEL); these studies also involve conducting pharmacokinetic/pharmacodynamic testing. The main focus of any preclinical program conducted is to support the analysis of a safe and effective dose range. Several toxicology studies provide data on the NOEL, i.e., the highest dose at which a drug exhibits no adverse effects. This dose level is further converted to an HED level on the basis of a comparative body-surface area if there is a lack of clinical pharmacokinetic data. Understanding the pharmacokinetic profile of a potential drug candidate plays an important role in the drug discovery program. Regulatory authorities play a major role in propelling the implementation of pharmacokinetic studies. These studies are also instrumental in optimizing pharmaceutical care services provided to patients admitted to hospitals. The pharmacokinetic model is often applied to determine exposure to drugs and concentrations of drugs to analyze optimal dosage and the disposition of drugs in the human body. Healthcare providers implement the principles of pharmacokinetic studies to monitor drug concentrations, determine doses of some drugs, maximize the intended therapeutic outcomes, and minimize toxicities. Thus, the expanding range of applications of pharmacokinetic studies bolsters the pharmacokinetics services market growth.
Pharmacokinetics Services Market Overview
The rising prevalence of chronic and infectious diseases, expanding application of pharmacokinetic studies, and outsourcing of pharmacokinetics services to contract research organizations boost the growth of the pharmacokinetics services market. According to the World Health Organization’s (WHO) 2024 data, ~422 million people in the world suffer from diabetes, and middle- and low-income countries account for most of these cases, causing approximately 1.5 million deaths every year. Pharmacokinetic studies are essential for understanding how drugs behave in a patient’s body by analyzing the process of absorption, distribution, metabolization, and elimination (ADME) within the human body.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Pharmacokinetics Services Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Pharmacokinetics Services Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Pharmacokinetics Services Market Drivers and Opportunities
Rising Prevalence of Chronic and Infectious Diseases Propel Market Growth
The growing prevalence of chronic diseases such as diabetes, cancer, and autoimmune diseases has been a prime enabler of drug development efforts across the world. According to the World Health Organization’s (WHO) 2024 data, ~422 million in the world suffer from diabetes, and these cases are mostly found in middle and low-income countries, causing approximately 1.5 million deaths every year. Pharmaceutical companies are at the forefront of developing drugs to treat various diseases. Pharmacokinetic studies are essential for understanding how these drugs behave in a patient’s body by analyzing the process of absorption, distribution, metabolization, and elimination (ADME) within the human body. The absorption of a drug into systemic circulation affects the speed and concentration at which a drug may reach the site of action, e.g., plasma. Drug distribution pattern throughout the body varies based on its biochemical properties and body physiology. Metabolism involves the processing of the drug by the body into subsequent compounds. This step is instrumental in converting the drug into water-soluble substances to render them suitable for renal clearance. Metabolism is also important for the conversion of prodrugs, such as codeine, into active metabolites. Excretion of drugs from the body is mainly governed by kidneys; however, in several cases, drugs may be excreted via the lungs, skin, or gastrointestinal tract. ADME dynamics define the bioavailability of drugs in the body, and the maintenance doses of drugs are calculated based on their clearance times (desired plasma concentration divided by bioavailability). Understanding of clearance allows practitioners to calculate appropriate dosing rates.
Pharmacokinetic studies focus on optimizing drug dose regimens in study subjects to understand the efficacy and safety of a drug. These studies are essential for ensuring the safety of drugs that are developed for long-term treatments, which helps evaluate the suitability and stability of drug formulations in chronic disease management. Hence, the rising burden of chronic and infectious diseases underlines the importance of pharmacokinetic studies to develop safe and effective personalized treatments.
Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics to Drive Market in Coming Years
The collection and handling of huge pharmacokinetic data generated during drug manufacturing are expensive, tedious, and time-consuming tasks. The labor- and cost-intensive nature of these tasks highlights the need for models such as pharmacokinetic simulation models and in vitro-in vivo pharmacokinetic correlation models (IVIVC) for the prediction of pharmacokinetic parameters. The pharmacokinetic simulation model is a tool that interprets drug kinetics in the living environment under specific conditions using computational and mathematical models. In addition, the IVIVC model are a fundamental part of the drug discovery process. Analyzing PK/PD predictions (i.e., pharmacokinetic/pharmacodynamic predictions) at the early stages of drug development is necessary for lead optimization strategies and also to further reduce attrition rates. There have been significant advancements in the development of new in-vitro and in-vivo strategies to improve and characterize pharmacokinetic properties. IVIVC models are being proposed as a cost-effective alternative to assess biopharmaceutical properties to analyze the bioavailability of drugs and determine their application. Hence, such in-vivo and in-vitro models are anticipated to provide lucrative opportunities for the pharmacokinetics services market in the near future.
Pharmacokinetics Services Market Share Analysis by Geography
The geographic scope of the pharmacokinetics services market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America. In North America, the pharmacokinetics services market is currently in the growth phase and experiencing exponential growth. The US accounts for the largest share of the pharmacokinetics services market in North America. The country has emerged as a leading clinical research destination; it accounts for ~50% of the total clinical trials conducted in the world. The availability of established medical infrastructure, fast approval timelines, and favorable regulatory framework create a conducive environment for pharmaceutical research companies to conduct clinical trials. Moreover, the data generated in trials conducted in the US is accepted globally. As per a World Health Organization (WHO) report, the US registered the highest number of clinical trials (157,618) in 2021. The rising number of research studies and clinical trials in North American countries is expected to have a positive impact on the pharmacokinetics services market in this region.
Pharmacokinetics Services Market Report Scope
Pharmacokinetics Services Market News and Recent Developments
The pharmacokinetics services market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the pharmacokinetics services market are mentioned below:
- Thermo Fisher Scientific expanded its clinical research operations with the opening of a state-of-the-art bioanalytical lab in Richmond, Virginia. The new unit will support the burgeoning demand generated in the biopharmaceutical ecosystem for consistent, high-quality laboratory services to accelerate drug development. The Richmond Bioanalytical Lab, whose entities have been operating since 1985, provides services for all phases of small molecule drug, biologics, vaccine, and biomarker development. Drug testing services include drug PK/PD, and immunogenicity and biomarker quantitation to support drug efficacy and safety. (Source: Thermo Fisher Scientific, Press Release, October 2022)
- Charles River Laboratories International, Inc., partnered with Kibur Medical to offer exclusive access to its implantable microdevice (IMD) for in vivo preclinical oncology studies. Kibur’s microdevice technology can hold up to 20 different compounds for local administration, which allows it to dose therapies directly into disease tissue, allowing for investigative studies of early-stage compounds where pharmacokinetic properties are poorly understood. (Source: Charles River Laboratories International, Inc., Newsletter, February 2021)
Pharmacokinetics Services Market Report Coverage and Deliverables
The “Pharmacokinetics Services Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering the following areas:
- Pharmacokinetics services market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Pharmacokinetics services market trends as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Pharmacokinetics services market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the pharmacokinetics services market
- Detailed company profiles
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The market, by condition, is categorized into melasma, solar lentigines, post-inflammatory hyperpigmentation, and others. The melasma segment held the largest Pharmacokinetics Services market share in 2023. It is further anticipated to register the highest CAGR during the forecast period.
The market, by end user, is categorized into hospitals, dermatology centers, and others. The hospitals segment held the largest market share in 2023, Further, the dermatology centers segment is anticipated to register the highest CAGR during the forecast period.
By treatment type, the market is segmented into cosmeceutical, light or laser therapy, microdermabrasion, chemical peels, cryotherapy, and others. The cosmeceutical segment held the largest Pharmacokinetics Services market share in 2023. Further, the microdermabrasion segment is anticipated to register the highest CAGR during the forecast period.
The Pharmacokinetics Services market was valued at US$ 6,676.23 million in 2023.
The Pharmacokinetics Services market is expected to be valued at US$ 11,788.50 million in 2030.
The Pharmacokinetics Services market majorly consists of the players, including Charles River Laboratories International Inc., Eurofins Scientific SE, Evotec SE, Certara Inc., Parexel International Corp, Thermo Fisher Scientific Inc., Allucent, PACIFIC BIOLABS, SGS SA, and Shanghai Medicilon Inc..
Factors such as the rising prevalence of chronic and infectious diseases, the expanding range of applications of pharmacokinetic studies, and the outsourcing of pharmacokinetics services to contract research organizations propel the market growth. However, the limited reach of pharmacokinetics service providers in emerging countries impedes the growth of the market.
Pharmacokinetics is the study of how the body absorbs, distributes, metabolizes, and excretes drugs. It is a crucial aspect of drug development as it helps determine the dosage, timing, and route of administration of a drug to achieve the desired therapeutic effect. Pharmacokinetic services include Data Management, Programming, and CDISC Dataset Creation, Noncompartmental PK Analysis (NCA), Population Pharmacokinetics (popPK), Analysis Plans, Dosing Simulations, Comprehensive Submission-Ready Packages for Regulatory Authorities, Designing and Interpreting Nonclinical and Clinical ADME Studies, and Bioanalytical Method Validation, Reports, and Compendial Analytical Methods.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Pharmacokinetics Services Market Landscape
4.1 PEST Analysis
5. Pharmacokinetics Services Market – Key Market Dynamics
5.1 Pharmacokinetics Services Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Rising Prevalence of Chronic and Infectious Diseases
5.2.2 Expanding Range of Application of Pharmacokinetic Studies
5.2.3 Outsourcing of Pharmacokinetics Services to CROs
5.3 Market Restraints
5.3.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
5.4 Market Opportunities
5.4.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
5.5 Future Trend
5.5.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
5.6 Impact of Drivers and Restraints:
6. Pharmacokinetics Services Market – Global Market Analysis
6.1 Pharmacokinetics Services Market Revenue (US$ Million), 2023–2031
7. Pharmacokinetics Services Market Analysis – by Drug Type
7.1 Overview
7.2 Small Molecule
7.2.1 Overview
7.2.2 Small Molecule: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Large Molecule
7.3.1 Overview
7.3.2 Large Molecule: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Vaccines
7.4.1 Overview
7.4.2 Vaccines: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8. Pharmacokinetics Services Market Analysis – by Service Type
8.1 Pre-Clinical ADME and Human Studies
8.1.1 Overview
8.1.2 Pre-Clinical ADME and Human Studies: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.2 PK/PD Analysis and Reporting
8.2.1 Overview
8.2.2 PK/PD Analysis and Reporting: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Dosing Simulations
8.3.1 Overview
8.3.2 Dosing Simulations: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Risk Analysis
8.4.1 Overview
8.4.2 Risk Analysis: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9. Pharmacokinetics Services Market Analysis – by Therapeutic Application
9.1 Oncology
9.1.1 Overview
9.1.2 Oncology: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.2 Infectious Diseases
9.2.1 Overview
9.2.2 Infectious Diseases: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.3 Neurological Disorders
9.3.1 Overview
9.3.2 Neurological Disorders: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.4 Autoimmune Diseases
9.4.1 Overview
9.4.2 Autoimmune Diseases: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.5 Gynecological Disorders
9.5.1 Overview
9.5.2 Gynecological Disorders: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.6 Cardiovascular Diseases
9.6.1 Overview
9.6.2 Cardiovascular Diseases: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.7 Respiratory Disorders
9.7.1 Overview
9.7.2 Respiratory Disorders: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.8 Others
9.8.1 Overview
9.8.2 Others: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10. Pharmacokinetics Services Market Analysis – by End User
10.1 Pharmaceutical and Biotechnology Companies
10.1.1 Overview
10.1.2 Pharmaceutical and Biotechnology Companies: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.2 Contract Research Organization
10.2.1 Overview
10.2.2 Contract Research Organization: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.3 Others
10.3.1 Overview
10.3.2 Others: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11. Pharmacokinetics Services Market – Geographical Analysis
11.1 North America
11.1.1 North America Pharmacokinetics Services Market Overview
11.1.2 North America: Pharmacokinetics Services Market – Revenue and Forecast Analysis – by Country
11.1.2.1 United States: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.1.2.1.1 Overview
11.1.2.1.2 United States: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.1.2.1.3 United States: Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.2.1.4 United States: Pharmacokinetics Services Market Breakdown, by Service Type
11.1.2.1.5 United States: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.2.1.6 United States: Pharmacokinetics Services Market Breakdown, by End User
11.1.2.2 Canada: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.1.2.2.1 Overview
11.1.2.2.2 Canada: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.1.2.2.3 Canada: Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.2.2.4 Canada: Pharmacokinetics Services Market Breakdown, by Service Type
11.1.2.2.5 Canada: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.2.2.6 Canada: Pharmacokinetics Services Market Breakdown, by End User
11.1.2.3 Mexico: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.1.2.3.1 Overview
11.1.2.3.2 Mexico: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.1.2.3.3 Mexico: Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.2.3.4 Mexico: Pharmacokinetics Services Market Breakdown, by Service Type
11.1.2.3.5 Mexico: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.2.3.6 Mexico: Pharmacokinetics Services Market Breakdown, by End User
11.2 Europe
11.2.1 Europe Pharmacokinetics Services Market Overview
11.2.2 Europe: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.3 Pharmacokinetics Services Market Breakdown by Countries
11.2.4 Pharmacokinetics Services Market Revenue and Forecast and Analysis – by Country
11.2.4.1 Germany: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.1.1 Overview
11.2.4.1.2 Germany: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.1.3 Germany: Pharmacokinetics Services Market Breakdown, by Drug Type
11.2.4.1.4 Germany: Pharmacokinetics Services Market Breakdown, by Service Type
11.2.4.1.5 Germany: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.2.4.1.6 Germany: Pharmacokinetics Services Market Breakdown, by End User
11.2.4.2 France: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.2.1 Overview
11.2.4.2.2 France: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.2.3 France: Pharmacokinetics Services Market Breakdown, by Drug Type
11.2.4.2.4 France: Pharmacokinetics Services Market Breakdown, by Service Type
11.2.4.2.5 France: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
The market for infectious diseases segment is estimated to be worth US$ 19.24 million by 2031 and is expected to register a CAGR of 10.8% during the 2023–2031.
11.2.4.2.6 France: Pharmacokinetics Services Market Breakdown, by End User
11.2.4.3 United Kingdom: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.3.1 Overview
11.2.4.3.2 United Kingdom: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.3.3 United Kingdom: Pharmacokinetics Services Market Breakdown, by Drug Type
11.2.4.3.4 United Kingdom: Pharmacokinetics Services Market Breakdown, by Service Type
11.2.4.3.5 United Kingdom: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.2.4.3.6 United Kingdom: Pharmacokinetics Services Market Breakdown, by End User
11.2.4.4 Italy: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.4.1 Overview
11.2.4.4.2 Italy: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.4.3 Italy: Pharmacokinetics Services Market Breakdown, by Drug Type
11.2.4.4.4 Italy: Pharmacokinetics Services Market Breakdown, by Service Type
11.2.4.4.5 Italy: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.2.4.4.6 Italy: Pharmacokinetics Services Market Breakdown, by End User
11.2.4.5 Spain: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.5.1 Overview
11.2.4.5.2 Spain: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.5.3 Spain: Pharmacokinetics Services Market Breakdown, by Drug Type
11.2.4.5.4 Spain: Pharmacokinetics Services Market Breakdown, by Service Type
11.2.4.5.5 Spain: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.2.4.5.6 Spain: Pharmacokinetics Services Market Breakdown, by End User
11.2.4.6 Rest of Europe: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.6.1 Overview
11.2.4.6.2 Rest of Europe: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.2.4.6.3 Rest of Europe: Pharmacokinetics Services Market Breakdown, by Drug Type
11.2.4.6.4 Rest of Europe: Pharmacokinetics Services Market Breakdown, by Service Type
11.2.4.6.5 Rest of Europe: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.2.4.6.6 Rest of Europe: Pharmacokinetics Services Market Breakdown, by End User
11.3 Asia Pacific
11.3.1 Asia Pacific Pharmacokinetics Services Market Overview
11.3.2 Asia Pacific: Pharmacokinetics Services Market
11.3.3 Asia Pacific: Pharmacokinetics Services Market – Revenue and Forecast Analysis – by Country
11.3.3.1 China: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.1.1 Overview
11.3.3.1.2 China: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.1.3 China: Pharmacokinetics Services Market Breakdown, by Drug Type
11.3.3.1.4 China: Pharmacokinetics Services Market Breakdown, by Service Type
11.3.3.1.5 China: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.3.3.1.6 China: Pharmacokinetics Services Market Breakdown, by End User
11.3.3.2 Japan: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.2.1 Overview
11.3.3.2.2 Japan: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.2.3 Japan: Pharmacokinetics Services Market Breakdown, by Drug Type
11.3.3.2.4 Japan: Pharmacokinetics Services Market Breakdown, by Service Type
11.3.3.2.5 Japan: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.3.3.2.6 Japan: Pharmacokinetics Services Market Breakdown, by End User
11.3.3.3 India: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.3.1 Overview
11.3.3.3.2 India: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.3.3 India: Pharmacokinetics Services Market Breakdown, by Drug Type
11.3.3.3.4 India: Pharmacokinetics Services Market Breakdown, by Service Type
11.3.3.3.5 India: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.3.3.3.6 India: Pharmacokinetics Services Market Breakdown, by End User
11.3.3.4 Australia: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.4.1 Overview
11.3.3.4.2 Australia: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.4.3 Australia: Pharmacokinetics Services Market Breakdown, by Drug Type
11.3.3.4.4 Australia: Pharmacokinetics Services Market Breakdown, by Service Type
11.3.3.4.5 Australia: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.3.3.4.6 Australia: Pharmacokinetics Services Market Breakdown, by End User
11.3.3.5 South Korea: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.5.1 Overview
11.3.3.5.2 South Korea: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.5.3 South Korea: Pharmacokinetics Services Market Breakdown, by Drug Type
11.3.3.5.4 South Korea: Pharmacokinetics Services Market Breakdown, by Service Type
11.3.3.5.5 South Korea: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.3.3.5.6 South Korea: Pharmacokinetics Services Market Breakdown, by End User
11.3.3.6 Rest of APAC: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.6.1 Overview
11.3.3.6.2 Rest of APAC: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.6.3 Rest of APAC: Pharmacokinetics Services Market Breakdown, by Drug Type
11.3.3.6.4 Rest of APAC: Pharmacokinetics Services Market Breakdown, by Service Type
11.3.3.6.5 Rest of APAC: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.3.3.6.6 Rest of APAC: Pharmacokinetics Services Market Breakdown, by End User
11.4 Middle East and Africa
11.4.1 Middle East and Africa Pharmacokinetics Services Market Overview
11.4.2 Middle East and Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3 Pharmacokinetics Services Market Breakdown by Countries
11.4.4 Pharmacokinetics Services Market Revenue and Forecast and Analysis – by Country
11.4.5 Middle East and Africa: Pharmacokinetics Services Market – Revenue and Forecast Analysis – by Country
11.4.5.1 Saudi Arabia: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.4.5.1.1 Overview
11.4.5.1.2 Saudi Arabia: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.4.5.1.3 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by Drug Type
11.4.5.1.4 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by Service Type
11.4.5.1.5 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.4.5.1.6 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by End User
11.4.5.2 South Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.4.5.2.1 Overview
11.4.5.2.2 South Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.4.5.2.3 South Africa: Pharmacokinetics Services Market Breakdown, by Drug Type
11.4.5.2.4 South Africa: Pharmacokinetics Services Market Breakdown, by Service Type
11.4.5.2.5 South Africa: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.4.5.2.6 South Africa: Pharmacokinetics Services Market Breakdown, by End User
11.4.5.3 United Arab Emirates: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.4.5.3.1 Overview
11.4.5.3.2 United Arab Emirates: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.4.5.3.3 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by Drug Type
11.4.5.3.4 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by Service Type
11.4.5.3.5 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.4.5.3.6 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by End User
11.4.5.4 Rest of Middle East and Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.4.5.4.1 Overview
11.4.5.4.2 Rest of Middle East and Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.4.5.4.3 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Drug Type
11.4.5.4.4 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Service Type
11.4.5.4.5 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.4.5.4.6 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by End User
11.5 South and Central America
11.5.1 South and Central America Pharmacokinetics Services Market Overview
11.5.2 South and Central America: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.5.3 Pharmacokinetics Services Market Breakdown by Countries
11.5.4 Pharmacokinetics Services Market Revenue and Forecast and Analysis – by Country
11.5.4.1 Brazil: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.5.4.1.1 Overview
11.5.4.1.2 Brazil: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.5.4.1.3 Brazil: Pharmacokinetics Services Market Breakdown, by Drug Type
11.5.4.1.4 Brazil: Pharmacokinetics Services Market Breakdown, by Service Type
11.5.4.1.5 Brazil: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.5.4.1.6 Brazil: Pharmacokinetics Services Market Breakdown, by End User
11.5.4.2 Argentina: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.5.4.2.1 Overview
11.5.4.2.2 Argentina: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.5.4.2.3 Argentina: Pharmacokinetics Services Market Breakdown, by Drug Type
11.5.4.2.4 Argentina: Pharmacokinetics Services Market Breakdown, by Service Type
11.5.4.2.5 Argentina: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.5.4.2.6 Argentina: Pharmacokinetics Services Market Breakdown, by End User
11.5.4.3 Rest of South and Central America: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.5.4.3.1 Overview
11.5.4.3.2 Rest of South and Central America: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.5.4.3.3 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by Drug Type
11.5.4.3.4 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by Service Type
11.5.4.3.5 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.5.4.3.6 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by End User
12. Company Profile
12.1 Charles River Laboratories InternationalInc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Eurofins Scientific SE
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Evotec SE
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Certara Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.5 Parexel International Corp
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Thermo Fisher Scientific Inc.
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Allucent
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 PACIFIC BIOLABS
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 SGS SA
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Shanghai Medicilon Inc.
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
List of Tables
Table 1. Pharmacokinetics Services Market Segmentation
Table 2. United States: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 3. United States: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 4. United States: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 5. United States: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 6. Canada: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 7. Canada: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 8. Canada: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 9. Canada: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 10. Mexico: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 11. Mexico: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 12. Mexico: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 13. Mexico: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 14. Germany: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 15. Germany: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 16. Germany: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 17. Germany: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 18. France: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 19. France: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 20. France: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 21. France: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 22. United Kingdom: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 23. United Kingdom: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 24. United Kingdom: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 25. United Kingdom: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 26. Italy: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 27. Italy: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 28. Italy: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 29. Italy: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 30. Spain: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 31. Spain: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 32. Spain: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 33. Spain: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 34. Rest of Europe: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 35. Rest of Europe: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 36. Rest of Europe: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 37. Rest of Europe: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 38. China: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 39. China: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 40. China: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 41. China: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 42. Japan: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 43. Japan: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 44. Japan: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 45. Japan: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 46. R&D Expenditure of Indian Companies, 2018–2020 (US$ Million)
Table 47. Company
Table 48. India: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 49. India: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 50. India: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 51. India: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 52. Australia: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 53. Australia: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 54. Australia: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 55. Australia: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 56. South Korea: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 57. South Korea: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 58. South Korea: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 59. South Korea: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 60. Rest of APAC: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 61. Rest of APAC: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 62. Rest of APAC: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 63. Rest of APAC: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 64. Saudi Arabia: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 65. Saudi Arabia: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 66. Saudi Arabia: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 67. Saudi Arabia: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 68. South Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 69. South Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 70. South Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 71. South Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 72. United Arab Emirates: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 73. United Arab Emirates: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 74. United Arab Emirates: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 75. United Arab Emirates: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 76. Rest of Middle East and Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 77. Rest of Middle East and Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 78. Rest of Middle East and Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 79. Rest of Middle East and Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 80. Brazil: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 81. Brazil: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 82. Brazil: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 83. Brazil: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 84. Argentina: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 85. Argentina: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 86. Argentina: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 87. Argentina: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
Table 88. Rest of South and Central America: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Drug Type
Table 89. Rest of South and Central America: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Service Type
Table 90. Rest of South and Central America: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by Therapeutic Application
Table 91. Rest of South and Central America: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million) – by End User
List of Figures
Figure 1. Pharmacokinetics Services Market Segmentation, by Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Pharmacokinetics Services Market Revenue (US$ Million), 2023–2031
Figure 5. Pharmacokinetics Services Market, By Geography Forecast Analysis, 2023 & 2031
Figure 6. Pharmacokinetics Services Market Share (%) – by Drug Type (2023 and 2031)
Figure 7. Small Molecule: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 8. Large Molecule: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 9. Vaccines: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 10. Pharmacokinetics Services Market Share (%) – by Service Type (2023 and 2031)
Figure 11. Pre-Clinical ADME and Human Studies: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 12. PK/PD Analysis and Reporting: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Dosing Simulations: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 14. Risk Analysis: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 15. Others: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 16. Pharmacokinetics Services Market Share (%) – by Therapeutic Application (2023 and 2031)
Figure 17. Oncology: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 18. Infectious Diseases: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 19. Neurological Disorders: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 20. Autoimmune Diseases: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 21. Gynecological Disorders: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 22. Cardiovascular Diseases: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 23. Respiratory Disorders: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 24. Others: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 25. Pharmacokinetics Services Market Share (%) – by End User (2023 and 2031)
Figure 26. Pharmaceutical and Biotechnology Companies: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 27. Contract Research Organization: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 28. Others: Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 29. North America: Pharmacokinetics Services Market by Key Countries – Revenue (2023) US$ Million
Figure 30. North America: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 31. North America: Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 32. United States: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 33. Canada: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 34. Mexico: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 35. Europe: Pharmacokinetics Services Market – Revenue by Key Countries Revenue 2023 (US$ Million)
Figure 36. Europe: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 37. Europe: Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 38. Germany: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 39. France: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 40. United Kingdom: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 41. Italy: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 42. Spain: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 43. Rest of Europe: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 44. Asia Pacific: Pharmacokinetics Services Market – Revenue by Key Countries 2023 (US$ Million)
Figure 45. Asia Pacific: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 46. Asia Pacific: Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 47. China: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 48. Japan: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 49. India: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 50. Australia: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 51. South Korea: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 52. Rest of APAC: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 53. Middle East and Africa: Pharmacokinetics Services Market by Key Countries – Revenue 2023 (US$ Million)
Figure 54. Middle East and Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 55. Pharmacokinetics Services Market Breakdown by Key Countries, 2023 and 2031 (%)
Figure 56. Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 57. Saudi Arabia: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 58. South Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 59. United Arab Emirates: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 60. Rest of Middle East and Africa: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 61. South and Central America: Pharmacokinetics Services Market by Key Countries – Revenue 2023 (US$ Million)
Figure 62. South and Central America: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 63. Pharmacokinetics Services Market Breakdown by Key Countries, 2023 and 2031 (%)
Figure 64. Brazil: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 65. Argentina: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 66. Rest of South and Central America: Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
The List of Companies - Pharmacokinetics Services Market
- Charles River Laboratories International Inc.
- Eurofins Scientific SE
- Evotec SE
- Certara Inc.
- Parexel International Corp
- Thermo Fisher Scientific Inc.
- Allucent
- PACIFIC BIOLABS
- SGS SA
- Shanghai Medicilon Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For